Peter's mailing address filed with the SEC is C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD, CA, 94545.
Over the last 4 years, insiders at Benitec Biopharma Inc have traded over $0 worth of Benitec Biopharma Inc stock and bought 409,597 units worth $1,496,765 . The most active insiders traders include Steven Michael Oliveira, J Kevin Buchi, and Edward F Smith. On average, Benitec Biopharma Inc executives and independent directors trade stock every 278 days with the average trade being worth of $1,152,330. The most recent stock trade was executed by J Kevin Buchi on 11 August 2023, trading 51,813 units of BNTC stock currently worth $437,302.
benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
Benitec Biopharma Inc executives and other stock owners filed with the SEC include: